R(+)-UH-301 is a potent and selective 5-HT1A serotonin receptor agonist and works as an antinociceptive agent. In the experiments on rats were shown, that R(+)-UH-301 significantly decrease formalin-induced flinching.

A-836339 is a drug that acts as a cannabinoid CB2 receptor-selective agonist; exhibits high potencies at CB(2) and selectivity over CB(1) receptor. It showed analgesic, anti-inflammatory and anti-hyperalgesic effects at low doses. A-836339 was detected in a certain product in Japan and was suggested to be for human consumption.

3-Methylcholanthrene a compound, which can activate both aryl hydrocarbon receptor (AhR) and estrogen receptor alpha. It is used to induce fibrosarcomas and skin carcinomas in laboratory animals. The daily exposure to 3-methylcholanthrene induced changes in both gene expression and epigenomic remodeling, which had led to premature ovarian failure.

GR 89696 is a potent and selective kappa-OR agonist. The (-)-isomer, GR103545, is the active enantiomer of GR89696. In a first-in-human Positron Emission Tomography study, [11C]GR103545 was shown to be a promising agent, which can be used to image and quantify kappa-OR in humans with brain disorders. The ( )-isomer of GR 89696 is inactive.

GW-4064 is a synthetic small molecule selective agonist of the orphan nuclear receptor FXR developed by GlaxoSmithKline. GW-4064-mediated FXR activation ameliorates diet-induced obesity, suppresses hepatic lipid accumulation, and maintains glucose and lipid homeostasis in C57BL/6 mice. GW-4064-treated tumors exhibited decreased levels of leptin-regulated proteins along with a strong staining intensity for SOCS3. Thus, FXR ligand GW-4064 might represent an emerging potential anti-cancer therapy able to block the tumor supportive role of activated fibroblasts within the breast microenvironment.

GW-9508 is a small-molecule agonist of the fatty acid receptors GPR40 and GPR120. GW-9508 exerts wide-range activity in animal models: anti-depressant, anti-inflammatory, anti-diabetic and analgetic actions.

(R)-SKF-83959 (MCL 202) is enantiomer of D1 receptor agonist SKF-83959. (R)-SKF-83959 is reported to be a functionally selective dopamine D1 and D5 receptors ligand with much lower affinity to dopamine D2 and D3 receptors. (R)-SKF-83959 like SKF-83959, produced dose related effects on overt behavior (eye blinking) and schedule-controlled performance in squirrel monkeys. (R)-SKF-83959 increases in eye blinking and decreases in rates of fixed-ratio responding. In contrast to the effects of its S-(-) enantiomer, was relatively devoid of behavioral activity up to doses that were approximately 10-fold greater than (R)-SKF-83959. Pretreatment with the selective D1- like receptor antagonist SCH 39166 dose-dependently antagonized increases in eye blinking produced by (R)-SKF-83959, confirming the involvement of D1 mechanisms in its effects.